Madrigal Pharmaceuticals
(NASDAQ) MDGL
Madrigal Pharmaceuticals Financials at a Glance
Market Cap
$12.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$1.13B
Net Income (TTM)
-$309.44M
EPS (TTM)
-$12.80
P/E Ratio
-41.93
Dividend
$0.00
Beta (Volatility)
0.94 (Low)
Dividend
$0.00
Beta (Volatility)
0.94 (Low)
Price
$535.75
Volume
294,015.079
Open
$564.94
Price
$535.75
Volume
294,015.079
Open
$564.94
Previous Close
$536.70
Daily Range
$529.50 - $564.94
52-Week Range
$286.44 - $615.00
Estimated Earnings Date
Aug 4, 2026
Dividend
$0.00
Beta (Volatility)
0.94 (Low)
Price
$535.75
Volume
294,015.079
Open
$564.94
Previous Close
$536.70
Daily Range
$529.50 - $564.94
52-Week Range
$286.44 - $615.00
Estimated Earnings Date
Aug 4, 2026
MDGL News
MDGL: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Madrigal Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
915
CEO
William J. Sibold, MBA
Website
www.madrigalpharma.comHeadquarters
West Conshohocken, PA 19428, US
MDGL Financials
Key Financial Metrics (TTM)
Gross Margin
93.07%
Operating Margin
-27.68%
Net Income Margin
-27.32%
Return on Equity
-50.15%
Return on Capital
-31.36%
Return on Assets
-25.21%
Earnings Yield
-2.38%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$12.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
23.06M
Volume
294.02K
Avg. Volume
328.62K
Financials (TTM)
Gross Profit
$1.05B
Operating Income
-$313.51M
EBITDA
-$281.09M
Operating Cash Flow
-$268.10M
Capital Expenditure
-$4.32M
Free Cash Flow
-$272.41M
Cash & ST Invst.
$817.93M
Total Debt
$347.31M
Madrigal Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$311.34M
+126.8%
Gross Profit
$284.49M
+114.3%
Gross Margin
91.38%
N/A
Market Cap
$12.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$13.52M
N/A
Employees
915
N/A
Net Income
-$94.39M
-28.9%
EBITDA
-$86.19M
-23.9%
Quarterly Fundamentals
Total Cash
$817.93M
-3.0%
Total Debt
$347.31M
+190.0%
Accounts Receivable
$187.36M
+205.0%
Inventory
$112.07M
+102.9%
Long Term Debt
$345.61M
+191.0%
Short Term Debt
$1.70M
+67.0%
Return on Assets
-25.21%
N/A
Return on Invested Capital
-35.26%
N/A
Free Cash Flow
-$171.28M
-92.7%
Operating Cash Flow
-$167.44M
-88.4%